Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in

Status Recruiting

Clinical Trial Summary

Prasugrel has a faster onset of action and greater platelet inhibition with less inter-individual response variability than clopidogrel. Japan and Taiwan are the only two nations where adjusted/Asian dose of prasugrel (loading dose (LD)/maintenance (MD): 20/3.75 mg) was approved for clinical use. However, there is no data regarding the effectiveness of adjusted dose of prasugrel on platelet reactivity in Taiwanese patients with acute coronary syndrome (ACS). This study aim to evaluate the pharmacodynamic of the Asian dose prasugrel on the platelet reactivity after percutaneous coronary intervention (PCI) for patients with ACS.

Clinical Trial Description

Rationale and Background Prasugrel provides more potent and rapid platelet inhibition compared to Clopidogrel. Rapid and effective inhibition of the platelet P2Y12 receptor is of pivotal importance in patients with AMI who undergo PCI. Prasugrel (60 mg loading and 10 mg/day maintenance dose) is a new generation P2Y12 inhibitor that achieves greater and faster platelet inhibition comparing with clopidogrel in patients undergoing PCI. As revealed by 2 head-to-head studies, reducing Prasugrel dosages to 20/3.75 LD/MD (mg) was still efficacious but led to less bleeding events than the original 60/10 LD/MD (mg). In TRITON-TIMI 38 trial, prasugrel was associated with not only significantly less ischemic events but also more non-CABG TIMI major bleeding, as compared to Clopidogrel. In the PRASFIT-ACS study from Japan (20 mg loading and 3.75 mg/day maintenance dose), prasugrel was associated with a 23% reduction of MACE and the incidence of non-CABG major bleeding was similar to clopidogrel. There is NO data regarding the effectiveness of Japanese loading dose of prasugrel on platelet reactivity in Taiwanese patients with AMI. This study use PRU for efficacy and ISTH major bleeding for safety evaluations; the anticipated results are prompt and effective platelet inhibition as well as comparably low bleeding rate. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04768582
Study type	Interventional
Source	Feng Yuan Hospital, Ministry of Health and Welfare
Contact	Ms. Hao-Yien Pan
Phone	+88625271180
Email	shine75726@gmail.com
Status	Recruiting
Phase	N/A
Start date	May 1, 2020
Completion date	May 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06013813` - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI	N/A
Recruiting	`NCT05846893` - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease	N/A
Recruiting	`NCT05412927` - AngelMed Guardian® System PMA Post Approval Study
Completed	`NCT02750579` - Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?	N/A
Completed	`NCT04102410` - Assessing Force-velocity Profile: an Innovative Approach to Optimize Cardiac Rehabilitation in Coronary Patients	N/A
Enrolling by invitation	`NCT03342131` - Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome	N/A
Recruiting	`NCT01218776` - International Survey of Acute Coronary Syndromes in Transitional Countries
Enrolling by invitation	`NCT04676100` - International CR Registry
Completed	`NCT03590535` - 5th Generation cTnT in ED ACS
Recruiting	`NCT05437900` - INSIGHTFUL-FFR Clinical Trial	Phase 4
Completed	`NCT05551429` - Factors Related to Participation in Cardiac Rehabilitation in Patients With Acute Coronary Syndrome
Terminated	`NCT04316481` - IDE-ALERTS Continued Access Study	N/A
Active, not recruiting	`NCT04475380` - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting	`NCT04852146` - Electronic Feedback for Data Restitution and Valorization to the Emergency Teams in Aquitaine.
Active, not recruiting	`NCT02892903` - In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?	N/A
Completed	`NCT04077229` - Piloting Text Messages to Promote Positive Affect and Physical Activity	N/A
Completed	`NCT02944123` - Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)	Phase 3
Not yet recruiting	`NCT02871622` - BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM	N/A
Active, not recruiting	`NCT02922140` - The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit	N/A
Completed	`NCT02673437` - Rivaroxaban ACS Specialist Cohort Event Monitoring Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Platelet Reactivity After an Eastern Asian Loading Dose of Prasugrel in Taiwanese ACS Patients — PREP-TAMI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms